We'd appreciate your feedback. Send feedback Subscribe to our newsletters and alerts


Annals of Pharmacy Practice and Pharmacotherapy

2024 Volume 4 Issue 2

Therapeutic Success Is Misclassified When Biomarkers Improve but the Medication Work Required from Patients Becomes Unsustainable


, ,
  1. Department of Clinical Pharmacy and Patient-Reported Outcomes, Faculty of Health Sciences, Copenhagen Business School, Copenhagen, Denmark.
  2. Department of Pharmacy Practice and Treatment Burden, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
  3. Department of Pharmaceutical Care and Health Outcomes, Faculty of Pharmacy, University of Zurich, Zurich, Switzerland.
Abstract

To develop a methodological approach for classifying treatment outcomes when biological or clinical markers improve while the work required to sustain treatment becomes difficult, disruptive, or unacceptable to patients. A construct-explicit methodological synthesis was undertaken across literature addressing treatment burden, patient work, patient-reported outcomes, medication adherence and persistence, surrogate endpoints, functional outcomes, patient preferences, and value assessment. Biological response, symptom or functional response, treatment workload, experienced treatment burden, persistence feasibility, and patient-valued benefit were treated as analytically distinct constructs. Rules were specified for recognizing discordance among these domains and for preventing adherence, biomarker change, or treatment-burden scores from being used as interchangeable proxies. No patient-level dataset was created, no empirical threshold was estimated, and no composite score was derived. Biological improvement can coexist with high treatment workload, reduced capacity to sustain treatment, limited functional improvement, or unfavorable patient evaluation. Conversely, demanding treatment can remain sustainable when its benefits are substantial, the workload is bounded or supported, and the patient considers the trade-off worthwhile. Observed adherence or persistence does not establish low treatment burden, and nonpersistence does not establish that burden caused discontinuation. Biomarker improvement represents biological response unless direct patient-important evidence or an adequately justified surrogate relationship supports broader inference. Sustainable treatment success is therefore better treated as a multidomain interpretation than as a synonym for favorable biological response. Health-outcome assessment can misclassify treatment success when biological improvement is recorded without examining the work required to produce and maintain it. Biological response, treatment-work sustainability, patient-important outcomes, and persistence should be measured separately before preference-sensitive weighting or value assessment. The proposed approach is a testable methodological specification rather than a validated scoring instrument.


How to cite this article
Vancouver
Larsen N, Mansour A, Fischer J. Therapeutic Success Is Misclassified When Biomarkers Improve but the Medication Work Required from Patients Becomes Unsustainable. Ann Pharm Pract Pharmacother. 2024;4(2):114-24. https://doi.org/10.51847/xB0VMtRha0
APA
Larsen, N., Mansour, A., & Fischer, J. (2024). Therapeutic Success Is Misclassified When Biomarkers Improve but the Medication Work Required from Patients Becomes Unsustainable. Annals of Pharmacy Practice and Pharmacotherapy, 4(2), 114-124. https://doi.org/10.51847/xB0VMtRha0
Articles
Therapeutic Approaches to Facilitating Expulsion of Distal Ureteric Stones
Annals of Pharmacy Practice and Pharmacotherapy
Vol 2 Issue 1, 2022 | Ravindra Ambardekar
Evaluation of Antidiabetic Drug Prescribing Practices in Primary Care Clinics in Rural South India
Annals of Pharmacy Practice and Pharmacotherapy
Vol 3 Issue 1, 2023 | Kumutha Theivasigamani
Comparative Evaluation of Oral Wound Dressing Materials: A Comprehensive Clinical Review
Annals of Pharmacy Practice and Pharmacotherapy
Vol 4 Issue 1, 2024 | Maria Pia Ferraz
Development of an RP-HPLC Method for Dapagliflozin and Metformin HCL Analysis
Annals of Pharmacy Practice and Pharmacotherapy
Vol 1 Issue 1, 2021 | Khagga Bhavyasri
Evaluation of Antibiotic Use and Financial Costs in University Hospital Intensive Care Units
Annals of Pharmacy Practice and Pharmacotherapy
Vol 4 Issue 1, 2024 | Viviana Hodoșan

About GalaxyPub

Find out more

Established in 2019, Galaxy Publication stands as a global academic publishing house focused on advancing scholarly work across medicine, nursing, and health sciences. Through its network of peer-reviewed journals, the organization brings together original research and academic contributions from scholars around the world, creating a shared space for knowledge exchange and intellectual collaboration.